Presented at #SVIN25: CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: https://t.co/ZHLCV9ukNU Editorial:

For anyone who has wanted a clear, authoritative summary of inflammation and cardiovascular disease, and where the science is heading, here it is. The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease. @JACCJournals

So much excitement in #venous #lymphatic workshop 🙌 #VSS2025 #SVM @EriFukayaMD @adityasharmamd

• Emerging therapies in development include RNA-based therapies (#pelacarsen, #olpasiran, #lepodisiran, #zerlasiran) and small molecule inhibitor therapy (#muvalaplin).

• Regardless of baseline LDL-C, when Lp(a) was elevated, risk of CHD events increased. Lp(a) may blunt the benefit of statin therapy. The absolute contribution of Lp(a) reduction to reduced risk of MACE was substantial (~25%) when baseline Lp(a) concentration was high.

• Regardless of baseline LDL-C, when Lp(a) was elevated, risk of CHD events increased. Lp(a) may blunt the benefit of statin therapy.

Who should we screen for Lp(a)? • Family or personal history of premature ASCVD • Family history of Lp(a) • Familial hypercholesterolemia • Decisions regarding PCSK9i initiation • Recurrent events despite optimal LLT • CAVS • Estimated 10-year risk by PCE is 5-20%

• Elevated Lp(a) as the quadruple hit: proatherosclerotic, procalcific, prothrombotic, and antiangiogenic effects. More calcification, restenosis, revascularization, and MALE.

• Approx. 1.4 billion people around the world have elevated Lp(a) >125 nmol/L / >50 mg/dL. • On a per particle basis, Lp(a) is ~6 times more athorgenic than LDL.

• Lp(a) is the most potent genetic risk factor for CAD, PAD, and Calcific Ao Stenosis. #CAD #PAD • Lp(a) levels are predominantly genetically determined. Lifestyle changes have no significant impact on Lp(a) levels.

Incredible keynote by @DrMichaelShapir at #VSS2025. It is clear that “Lp(a) is the risk factor we can no longer ignore.” Here are some key takeaways. #SVM #VSS2025 @SVM_tweets #Lpa #atherosclerosis #vascular

We’re having a great time at #VSS2025! #SVM @SVM_tweets

As a #VSS2025 Social Media Moderator, I wanted to highlight 2 talks today among the many other fantastic sessions: Lp(a): re-writing the Vascular Risk Equation by @DrMichaelShapir @ 11:30 AM & Venous Vasc Medicine Symposium I: Nuts & Bolts of Clinical Practice @ 2 PM @SVM_tweets

Packed house at the @philadelphia @Loews_Hotels for @danrader333 keynote on novel therapeutics in vascular medicine @SVM_tweets #VSS2025 @PennMedicine

When a patient requests to see their ultrasound, it’s always a valuable teaching moment. Thanks to @FahadAlKhalfan for modeling and @sthomas013s for the caption. #SVM #VSS2025 @SVM_tweets

It’s SVM #VSS2025 week! Hope you all are excited for #science #learning #mentorship & some #fun 🥰 Don’t forget to share your VSS experience on social media by adding #VSS2025 to your posts. It’s a great way to connect with fellow attendees. Agenda @ https://t.co/4I79K5cNFg

Excited to share our publication in @JVSVL, Indications, technical aspects, and outcomes of stent placement in chronic iliofemoral venous obstruction.

Don't miss the next EAVLA Webinar happening Saturday, April 20th at 12:00pm ET. Register here: https://t.co/oa1sdjXGBF

Congratulations to Dr. Kamat @SamirKamat6 for his publication on dermatologic drug innovation published in @JAMADerm! #FDA #dermatology #dermtwitter

Our study of 13,731 patients undergoing varicose vein ablation shows that the location of treatment, whether above or below the knee, has a significant impact on patient-reported outcomes and clinical improvement. Very thankful for the phenomenal team that worked on this.